Suchergebnisse - "van de Donk, Niels W C J"

PubPharm (39)

1

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

enthalten in: The New England journal of medicine | 2024

von Sonneveld, P. | Dimopoulos, M. | Boccadoro, M. | +141

CommentIn: N Engl J Med. 2024 Apr 18;390(15):1440. - PMID 38631009

2

Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab : part 3 of the open-label, multicenter, phase 1b PAVO study

enthalten in: Leukemia & lymphoma | 2023

von Nahi, H. | Usmani, S. | Mateos, M. | +10

3

Prognostic value of minimal residual disease negativity in myeloma : combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

enthalten in: Blood | 2022

von Cavo, M. | San-Miguel, J. | Usmani, S. | +24

CommentIn: Blood. 2022 Feb 10;139(6):799-802. - PMID 35142848

4

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma

enthalten in: Blood advances | 2021

von Frerichs, K. | Minnema, M. | Levin, M. | +11

5

Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies : the laboratory solution to eliminate interference

enthalten in: Clinical chemistry and laboratory medicine | 2021

von Noori, S. | Verkleij, C. | Zajec, M. | +8

6

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA) : an open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Moreau, P. | Hulin, C. | Perrot, A. | +49

CommentIn: Nat Rev Clin Oncol. 2021 Nov;18(11):676. - PMID 34545220

7

Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma : The Hovon 143 Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021

von Stege, C. | Nasserinejad, K. | van der Spek, E. | +22

8

Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study

enthalten in: Haematologica | 2021

von Hulin, C. | Offner, F. | Moreau, P. | +20

9

Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma : Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)

enthalten in: Haematologica | 2021

von San-Miguel, J. | Usmani, S. | Mateos, M. | +14

10

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients

enthalten in: Cancers | 2021

von Frerichs, K. | Verkleij, C. | Dimopoulos, M. | +6